Sales force a ‘critical element’ of Pfizer’s five-year plan

Share this article:
As industry analysts continue to examine how manufacturers can justify large-scale sales force investment, Pfizer said it has no plans to scale back on its sales force, at least for the next three to five years.
"We've got plenty to do over the next three to five years, which is kind of our strategic horizon, and the field force is going to be a critical element in that mix," Pfizer's chief executive Henry McKinnell said during the company's fourth quarter earnings call to analysts.
But Pfizer's notion that its sales force will remain fully intact is not a plan that is set in stone.
"We always look at ways to improve the capability and structure of our field force," said McKinnell.
Pfizer is expected to provide further guidance on its 2005 strategy at an analysts meeting on April 5.
However, events like the February FDA advisory committee meeting on COX-2 drugs could have an impact on Pfizer's spending on sales activities, McKinnell said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.